Acadia Pharma (ACAD) Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Acadia Pharmaceuticals Inc. today announced that Health Canada has accepted its New Drug Submission for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health.
A pilot study suggests the ketogenic diet may ease symptoms of schizophrenia and bipolar disorder and reduce weight gain associated with metabolic syndrome.